Compare TC & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TC | LITS |
|---|---|---|
| Founded | 2010 | 2000 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.8M | 36.3M |
| IPO Year | 2018 | 2003 |
| Metric | TC | LITS |
|---|---|---|
| Price | $1.26 | $1.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 729.9K |
| Earning Date | 11-03-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 13.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $148,908.44 | N/A |
| Revenue Next Year | $4.24 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.20 | $0.69 |
| 52 Week High | $19.99 | $2.26 |
| Indicator | TC | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 27.44 | 46.87 |
| Support Level | N/A | $1.12 |
| Resistance Level | $2.69 | $1.25 |
| Average True Range (ATR) | 0.34 | 0.07 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 1.69 | 14.52 |
Token Cat Ltd has two reportable business segments: automotive electronics resale business and advertising business. The automotive electronics resale business focuses on sourcing, holding, and reselling automotive electronics products, and includes sales of automotive electronic component equipment and accessories, mainly consisting of communication device and power module. The Company procures products from third-party suppliers and resells them to customers through its sales channels. The advertising business currently consists mainly of proxy advertising services, through which the Company helps clients promote their brands, services and products on third-party online platforms. The automotive electronics resale business segment generates maximum revenue.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients. The company operates in the segments: Digital Asset Treasury Strategy and Development of Pharmaceutical Products.